Peter DiLaura

Peter DiLaura is the CEO and Board Director of Helicore Biopharma, a San Mateo biotech building long-acting antibody-peptide conjugates that go after obesity by neutralizing the GIP hormone in the bloodstream rather than blocking its receptor. With nearly three decades of company-building behind him - CEO roles at Initial Therapeutics and Second Genome, business and strategy chief at Sonoma Biotherapeutics, and time as an Entrepreneur-in-Residence at Third Rock Ventures - he is the operator brought in to turn a $65M Series A and a clinic-ready antibody into medicines that aim for quarterly dosing and better-quality weight loss.